|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|
| Assets: | ||||||||
| Current assets: | ||||||||
| Cash | ||||||||
| Deferred offering cost | ||||||||
| Prepaid expenses | ||||||||
| Due from related party | ||||||||
| Investments held in Trust Account | ||||||||
| Total current assets | ||||||||
| Long term prepaid expense | ||||||||
| Investments held in Trust Account | ||||||||
| Total assets | ||||||||
| Liabilities, Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit | ||||||||
| Current liabilities: | ||||||||
| Accrued offering costs and expenses | ||||||||
| Promissory note - related party | ||||||||
| Accrued expenses | ||||||||
| Promissory note - related party, net | ||||||||
| Working Capital Loan | ||||||||
| Due to related party | ||||||||
| Promissory note - third party, net | ||||||||
| Deferred underwriting commissions | ||||||||
| Total current liabilities | ||||||||
| Deferred underwriting commissions | ||||||||
| Total liabilities | ||||||||
| Class A ordinary shares subject to possible redemption, 485,593 and 11,500,000 shares at $10.74 and $10.15 redemption value as of June 30, 2023 and December 31, 2022, respectively | ||||||||
| Common stock | ||||||||
| Common Class A | ||||||||
| Common Class B | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ||||||||
| Total shareholders’ deficit | ||||||||
| Total Liabilities, Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit |
Loading...
